Armenia vs Brunei Darussalam: Prevalence rate of hypertension in women aged 30-79
Armenia
46.2
in 2019
Brunei Darussalam
45.6
in 2019
Armenia rank
16th
Brunei Darussalam rank
17th
Prevalence rate of hypertension in women aged 30-79 over time
- Armenia
- Brunei Darussalam
How they compare
Armenia currently reports 46.2 against 45.6 in Brunei Darussalam, a difference of 0.6.
Across all 30 years both countries report, Armenia has been ahead every year.
Armenia ranks 16th and Brunei Darussalam ranks 17th of 195 countries.
Armenia has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Armenia | Brunei Darussalam | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 43.17 | 36.93 | 6.24 | Armenia |
| 2000s | 45.09 | 40.45 | 4.64 | Armenia |
| 2010s | 46.36 | 44.27 | 2.09 | Armenia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence rate of hypertension in women aged 30-79, Armenia or Brunei Darussalam?
- Armenia, at 46.2 against 45.6 in Brunei Darussalam as of 2019.
- What is the difference in prevalence rate of hypertension in women aged 30-79 between Armenia and Brunei Darussalam?
- 0.6, with Armenia ahead.
- How many years of comparable data are there for Armenia and Brunei Darussalam?
- 30 years are reported by both, from 1990 to 2019.
- How do Armenia and Brunei Darussalam rank globally for prevalence rate of hypertension in women aged 30-79?
- Armenia ranks 16th and Brunei Darussalam ranks 17th of 195 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Prevalence rate of hypertension in women aged 30-79. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated share of female population with hypertension, based on population representative surveys and statistical modeling. Hypertension is a risk factor for chronic complications, including cardiovascular disease, and premature death.